Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

Hiam Chemaitelly; Houssein H. Ayoub; Sawsan AlMukdad; Jeremy Samuel Faust; Patrick Tang; Peter Coyle; Hadi M. Yassine; Asmaa A. Al Thani; Hebah A. Al-Khatib; Mohammad R. Hasan; Zaina Al Kanaani; Einas Al‐Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F. Abdul Rahim; Gheyath K. Nasrallah; Mohamed Ghaith Al‐Kuwari; Adeel A. Butt; Hamad Eid Al‐Romaihi; Mohamed H. Al‐Thani; Abdullatif Al‐Khal; Roberto Bertollini; Laith J. Abu‐Raddad

doi:10.1093/jtm/taad106

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune imprinting effects, or both, may explain findings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chemaitelly et al. (2023) studied this question.

synapsesocial.com/papers/6aacf6392c7588f69e24a068 https://doi.org/10.1093/jtm/taad106

View Full Paper

Ask AI

Bookmark

Share

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

Ask about this paper

Abstract

Discussion

Cite This Study

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading